Jatenzo EMA vs FDA Approach: Regulatory Differences, Label Requirements, and Safety Obligations

What Is Jatenzo and Why Does the Regulatory Comparison Matter?

Jatenzo is a novel oral formulation of testosterone undecanoate (TU) designed to achieve lymphatic absorption, bypassing first-pass hepatic metabolism. Prior oral testosterone products failed in the United States because hepatic first-pass clearance produced dangerously variable serum levels. Jatenzo resolves that problem through a self-emulsifying drug delivery system that directs absorption through intestinal lymphatics.

The regulatory comparison between the FDA and EMA matters for prescribers because each agency's label reflects different evidentiary standards, different post-market obligations, and different risk communication choices. A clinician who understands both frameworks can make more accurate risk-benefit decisions for individual patients.

Why Earlier Oral TU Did Not Satisfy FDA Standards

The EMA had previously approved oral testosterone undecanoate under the brand name Andriol (40 mg soft gelatin capsules) [1]. That product required multiple daily doses and showed highly variable pharmacokinetics. The FDA declined to approve Andriol-type formulations in the United States specifically because absorption was too erratic to reliably achieve eugonadal testosterone concentrations. Jatenzo's self-emulsifying system was designed to address those shortcomings, and the FDA required a dedicated pharmacokinetic program before considering an NDA.

The Lymphatic Absorption Advantage

When taken with a meal containing at least 30% fat calories, Jatenzo is packaged into chylomicrons in the gut wall and transported via lymphatics into the thoracic duct, bypassing the portal circulation entirely [2]. This mechanism is the pharmacological basis for the food requirement on the label and for the twice-daily dosing schedule.

FDA Approval: Timeline, NDA, and Key Trial

The FDA approved Jatenzo on March 28, 2019, under NDA 210-551 [3]. The approval was granted to Clarus Therapeutics (now Tolmar) for the indication of hypogonadism due to an identified medical condition in adult males. The agency did not approve Jatenzo for age-related low testosterone, a deliberate policy choice consistent with the FDA's 2015 label update requiring all testosterone products to specify a structural or genetic cause.

Swerdloff et al. (2020): The Key PK Trial

The primary clinical pharmacology data supporting the NDA came from the trial reported by Swerdloff and colleagues in the Journal of Clinical Endocrinology and Metabolism [4]. In that study, 166 hypogonadal men (baseline total testosterone <300 ng/dL) received Jatenzo dose-titrated to achieve testosterone within the eugonadal range. At the end of the titration and maintenance period, 87% of participants achieved a 24-hour average testosterone concentration (C avg) within 300 to 1,050 ng/dL. The geometric mean C avg was 489 ng/dL. Critically, C max values were substantially lower than those seen with injectable testosterone cypionate, reducing the supraphysiologic peak exposure that contributes to erythrocytosis and hematocrit elevation [4].

Hematocrit increases of 3 percentage points or more occurred in 22% of participants. That figure informed the label's hematocrit monitoring requirement: baseline, 3 to 6 months, and annually thereafter [3].

Blood Pressure Findings That Shaped the Label

Systolic blood pressure increased by a mean of 4 to 5 mmHg from baseline across the titration phase. This finding was not dismissed as noise. The FDA required a specific boxed-level hypertension warning and a structured monitoring schedule: blood pressure measurement at 3 to 4 weeks after initiation, at 3 months, and periodically after that [3]. Prescribers must be prepared to manage hypertension with antihypertensive therapy or Jatenzo dose reduction if blood pressure rises to Stage 2 levels (systolic ≥140 mmHg) [3].

The Jatenzo Label: Key Requirements and Risk Language

The full Jatenzo prescribing information is publicly available through the FDA's Drugs@FDA database [3]. The label carries several clinically consequential requirements.

Dosing and Titration Protocol

The starting dose is 237 mg twice daily with food. At 28 days, a serum testosterone level is drawn 6 hours after the morning dose. If that value falls below 400 ng/dL, the dose is increased to 316 mg BID. If the value exceeds 800 ng/dL, the dose is reduced to 158 mg BID. Doses above 396 mg BID are not approved [3].

The food requirement is not a suggestion. A pharmacokinetic sub-study showed that administration in a fasted state reduced C max by approximately 44% compared with a standard high-fat meal [4]. Patients should be counseled that skipping the meal effectively converts a therapeutic dose into a subtherapeutic one.

Cardiovascular Risk Warning Language

The FDA label for Jatenzo includes a Warning and Precaution stating: "Increases in blood pressure can occur with testosterone therapy, and these increases may be associated with major adverse cardiovascular events (MACE) including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death" [3]. This language is product-specific to Jatenzo and goes beyond the general testosterone class warning because the key trial demonstrated a measurable mean BP elevation.

The FDA's 2015 label update across all testosterone products had already added language about MACE risk [5]. For Jatenzo, the agency added the blood pressure monitoring schedule on top of that class-level text, making Jatenzo's cardiovascular risk communication more granular than most other testosterone formulations.

Contraindications

Jatenzo is contraindicated in men with breast cancer or known or suspected prostate cancer [3]. It is also contraindicated in women, as testosterone undecanoate causes fetal harm and virilization. The label specifically calls out that Jatenzo has not been evaluated in males <18 years of age [3].

EMA Approach: How European Regulation of Oral TU Differs

The EMA does not have a separate approval for Jatenzo as a distinct product in the European Union. The EU market has long had access to oral testosterone undecanoate through Andriol Testocaps (40 mg capsules, Organon), which received its initial authorization decades before Jatenzo's formulation existed [1]. Understanding why these two oral TU products received such different regulatory treatment illuminates the divergence between the two agencies.

Different Pharmacokinetic Standards Over Time

The EMA approved Andriol Testocaps under pharmacokinetic standards that were acceptable in the 1970s and 1980s, when demonstrating a general androgen effect was considered sufficient. The FDA, operating under stricter modern bioequivalence and PK requirements, applied a 24-hour testosterone concentration profile standard when evaluating Jatenzo. This difference in evidentiary rigor means the two agencies were, in effect, evaluating different questions about similar molecules.

EMA Cardiovascular Risk Communication for Testosterone

The EMA's Committee for Medicinal Products for Human Use (CHMP) conducted a class-level review of testosterone products in 2014 to 2015, parallel to the FDA's own review [6]. The CHMP concluded that testosterone products should carry warnings about cardiovascular risk, including polycythemia and potential thromboembolic events. However, the EMA's product-level label for Andriol Testocaps does not include a structured blood pressure monitoring schedule comparable to what the FDA required for Jatenzo, because the EMA's review predated Jatenzo's clinical data [6].

Post-Market Surveillance Differences

The FDA required Tolmar/Clarus to conduct a cardiovascular outcomes study as a post-market commitment, to be analyzed through the FDA Sentinel System, which links electronic health records and insurance claims data across tens of millions of patients [7]. The Sentinel System allows the FDA to detect pharmacovigilance signals at a population scale that pre-approval trials cannot achieve. The EMA's equivalent post-authorization safety studies (PASS) for Andriol Testocaps are generally narrower in scope and do not use a comparably integrated data infrastructure [6].

The table below summarizes the key regulatory divergences at a glance.

| Feature | FDA (Jatenzo NDA 210-551) | EMA (Andriol Testocaps EPAR) | |---|---|---| | Approval year | 2019 | 1970s (original); updated periodically | | Formulation | Self-emulsifying oral TU 158 to 396 mg BID | Soft gelatin capsule oral TU 40 mg | | PK standard | 24-hour C avg within 300 to 1,050 ng/dL | General androgen effect demonstrated | | BP monitoring schedule | Required at 3 to 4 weeks, 3 months, then periodic | Not mandated in a structured schedule | | Post-market CV outcomes study | Required (Sentinel-based) | PASS required; narrower scope | | Indication specificity | Medical cause of hypogonadism required | Hypogonadism (broader) | | Pediatric use | Specifically not evaluated (<18) | Not indicated |

Cardiovascular Safety: What the Evidence Actually Shows

Testosterone therapy and cardiovascular risk has been the most contested area in endocrinology regulation for over a decade. The FDA's 2015 action was triggered in part by the Vigen et al. Observational study [8] and the Finkle et al. Insurance claims analysis [9], both of which suggested elevated MACE risk in men using testosterone. Those findings were disputed, but the regulatory response was not reversed.

The TRAVERSE Trial Context

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, tested testosterone replacement in men with hypogonadism and elevated cardiovascular risk [10]. TRAVERSE found that testosterone therapy was non-inferior to placebo for MACE at a mean follow-up of 33 months. The primary endpoint rate was 7.0% in the testosterone group versus 7.3% in the placebo group (hazard ratio 0.96; 95% CI 0.78 to 1.17) [10]. This was the largest cardiovascular safety trial of testosterone replacement ever conducted.

TRAVERSE's results are relevant to Jatenzo because they provide the strongest evidence to date that testosterone replacement at eugonadal doses does not significantly increase MACE risk in a monitored population. The FDA has not yet updated Jatenzo's label to reflect TRAVERSE, but clinicians can cite TRAVERSE data when counseling patients about cardiovascular risk [10].

Blood Pressure Remains a Distinct Concern

TRAVERSE also found that atrial fibrillation occurred at a higher rate in the testosterone arm (3.5% vs 2.4%; P<0.001 by the trial's reporting) [10]. Blood pressure elevation, the specific signal that drove Jatenzo's monitoring requirement, is a separate concern from global MACE risk. A 4 to 5 mmHg sustained systolic elevation in a hypertensive patient could tip that patient into a higher-risk category over years, even if the aggregate MACE hazard ratio does not reach significance in a 33-month trial.

Erythrocytosis and Venous Thromboembolism

Testosterone therapy raises hematocrit by stimulating erythropoiesis, a well-documented effect [11]. The FDA label for Jatenzo states that therapy should be discontinued if hematocrit exceeds 54% [3]. Elevated hematocrit increases blood viscosity and is a recognized risk factor for venous thromboembolism (VTE). A 2023 pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) identified VTE as a disproportionately reported event across all testosterone formulations [12].

Prescribing Implications: Choosing Jatenzo Over Other TRT Formulations

Jatenzo occupies a specific niche in the testosterone therapy spectrum. It is the only FDA-approved oral testosterone option for men who prefer to avoid injections, gels, or patches while still achieving reliable eugonadal concentrations.

Who Is a Candidate

Men with confirmed primary or secondary hypogonadism (morning testosterone <300 ng/dL on two separate measurements, per Endocrine Society guidelines [13]) who have a documented medical cause, a preference for oral administration, and no history of poorly controlled hypertension are the most suitable candidates. Men with baseline systolic BP above 130 mmHg should be counseled specifically about the 4 to 5 mmHg mean elevation observed in the key trial [4].

Practical Monitoring Schedule for Clinicians

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends monitoring total testosterone, hematocrit, PSA, and symptom response at 3 to 6 months after initiation and then annually [13]. For Jatenzo specifically, the FDA label adds blood pressure to that monitoring schedule with its own timeline [3]. Prescribers should therefore check:

• Serum testosterone (6-hour post-morning-dose trough): day 28, then every 3 to 6 months
• Hematocrit: baseline, 3 to 6 months, annually
• Blood pressure: 3 to 4 weeks, 3 months, then at every scheduled visit
• PSA: baseline, 3 to 6 months, then per Endocrine Society schedule
• Lipids: annually (testosterone reduces HDL in some patients) [13]

Drug Interactions Unique to Oral TU

Because Jatenzo is absorbed via lymphatics rather than portal circulation, hepatic CYP3A4 interactions that affect other oral androgens are less prominent. However, testosterone is a substrate for CYP3A4 during systemic metabolism, and concurrent use of strong CYP3A4 inhibitors (such as ketoconazole or ritonavir) may still raise testosterone exposure above the intended range [3]. Clinicians managing patients on antiretroviral therapy should check the testosterone level more frequently in the first 90 days.

FDA Post-Market Obligations and Sentinel Surveillance

As a condition of the March 2019 approval, the FDA required Clarus/Tolmar to conduct a post-market cardiovascular safety study using the FDA Sentinel System [7]. The Sentinel System is a distributed database covering over 100 million patients' electronic health records and insurance claims, maintained under the FDA Safety Reporting Enhancement Act [7]. This requirement reflects the agency's recognition that the key PK trial (N=166) was powered for pharmacokinetic endpoints, not cardiovascular outcomes.

The practical implication for prescribers is that real-world Jatenzo use is being monitored at a population level. Clinicians who document diagnoses accurately (using ICD-10 codes for male hypogonadism, E29.1) and record blood pressure changes at follow-up visits contribute indirectly to the pharmacovigilance signal quality captured by Sentinel-linked data systems.

The EMA has no equivalent mandatory Sentinel-based commitment for Andriol Testocaps. European post-authorization studies for that product rely on voluntary adverse event reporting to national competent authorities and EudraVigilance, the EU's centralized pharmacovigilance database, which has lower event capture rates than Sentinel for chronic conditions [6].

Labeling Differences That Matter to Compounding and Telehealth

Several telehealth and compounding pharmacy platforms have marketed compounded oral testosterone undecanoate as a lower-cost alternative to Jatenzo. The FDA has explicitly stated that compounded testosterone products are not approved and do not carry the same labeling, manufacturing quality, or post-market surveillance obligations as Jatenzo [14]. The FDA's guidance on compounded testosterone notes that compounded products may not achieve the same pharmacokinetic profile as the approved formulation, even when the active ingredient is nominally identical [14].

This distinction matters for telehealth prescribers in particular. A patient receiving compounded oral TU from an out-of-state pharmacy is receiving a product with no FDA-reviewed label, no mandated BP monitoring requirement, and no contributing data to the Sentinel cardiovascular safety study. Prescribers bear the full clinical and medicolegal responsibility for monitoring in those cases.